Clinical Trial Update: Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating topical WR-279,396 for cutaneous leishmaniasis has been completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Leishmaniasis

Drugs mentioned

• WR 279,396

Snippet

Sponsor: U.S. Army Medical Research and Development Command | Conditions: Cutaneous Leishmaniasis | Phase 2 | Status: COMPLETED | Results posted: 2017-02-15